Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury
CNS Neuroscience & Therapeutics · 2026-08 · 32 (8)
DOI: 10.1002/cns.71086 ↗At a glance
Journal article in CNS Neuroscience & Therapeutics, published online on 2026-08-13. Written by Wenjie Lu and 9 co-authors. Institution: Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Medical University, …. Major MEDLINE topics: Spinal Cord Injuries, Toll-Like Receptor 4, NF-kappa B, Nerve Tissue Proteins. 53 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Funding of China, Zhejiang Medical and Health Science and Technology Plan Project, National College Students Innovation and Entrepreneurship Training Program.
Abstract (original language)
Aims
Spinal cord injury (SCI) can cause severe neurological dysfunction and the occurrence of chronic neuropathic pain, which can manifest as the occurrence of abnormal pain and hyperalgesia. Artemin (ARTN) is a member of the glial cell‐derived neurotrophic factor (GDNF) family ligand and can improve neural injury and regulate the occurrence of neuropathic pain. However, the process by which ARTN regulates inflammation and the sensitization of the dorsal horn of the spinal cord related to pain after SCI is still unclear.
Methods
ARTN‐Fc fusion protein was constructed and administered intrathecally to mice after SCI. Motor recovery and pain‐related behaviors were evaluated using behavioral, gait, electrophysiological, paw withdrawal latency, and formalin‐induced Fos assays. Molecular changes were assessed by Western blotting, immunofluorescence, and immunohistochemistry. In vitro, a BV2–PC12 Transwell co‐culture system was used to examine the effect of ARTN‐Fc on activated microglia‐mediated neuronal injury.
Results
ARTN‐Fc treatment significantly improved motor recovery and reduced thermal hyperalgesia after SCI. Mechanistically, ARTN‐Fc promoted microglial M2 polarization, inhibited TLR4/NF‐κB activation, suppressed pro‐inflammatory cytokine expression, and attenuated NLRP3 inflammasome/pyroptosis‐related signaling. In the spinal dorsal horn, ARTN‐Fc increased inhibitory GABAergic markers, including vGAT and GAD1, while reducing the excitatory marker vGluT2, suggesting altered inhibitory/excitatory synaptic marker expression. In vitro, ARTN‐Fc reduced neuronal apoptosis mediated by activated microglia.
Conclusion
Taken together, the results suggest that ARTN‐Fc is a potential therapeutic agent for SCI repair and neuropathic pain treatment by inhibiting the TLR4/NF‐κB pathway to suppress neuroinflammation and modulating inhibitory/excitatory synaptic marker expression in the spinal dorsal horn.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
- State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
- The Second Clinical School of Wenzhou Medical University, Wenzhou, China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Funding
- National Natural Science Funding of China
- Zhejiang Medical and Health Science and Technology Plan Project
- National College Students Innovation and Entrepreneurship Training Program
- Wenzhou Major Science and Technology Innovation Project Approval Project
Cite
APA
Lu, W., Tu, Y., Wang, R., Jiang, M., Zhuang, J., Song, J., Wu, P., Sheng, S., Zhu, S., & Wang, Z. (2026). Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury. CNS Neuroscience & Therapeutics, 32(8). https://doi.org/10.1002/cns.71086
Vancouver
Lu W, Tu Y, Wang R, Jiang M, Zhuang J, Song J, et al. Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury. CNS Neuroscience & Therapeutics. 2026;32(8). doi:10.1002/cns.71086
BibTeX
@article{Lu2026,
author = {Lu, Wenjie and Tu, Yurong and Wang, Renkai and Jiang, Minghao and Zhuang, Junyu and Song, Jiahui and Wu, Ping and Sheng, Sunren and Zhu, Sipin and Wang, Zhouguang},
title = {Recombinant Artemin‐Fc Fusion Protein Attenuates TLR4 / NF ‐ κB ‐Associated Neuroinflammation and Modulates Inhibitory/Excitatory Synaptic Marker Expression After Spinal Cord Injury},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {8},
doi = {10.1002/cns.71086}
}
EUVIMED